Improving adherence in mood disorders: The struggle against relapse, recurrence and suicide risk

Expert Review of Neurotherapeutics

Volumn 9, Issue 7, 2009, Pages 985-1004

  Pompili, Maurizio ^a,b   Serafini, Gianluca ^a   Del Casale, Antonio ^a   Rigucci, Silvia ^a   Innamorati, Marco ^c   Girardi, Paolo ^a   Tatarelli, Roberto ^a   Lester, David ^d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b MCLEAN HOSPITAL   (United States)

^c Universita' Europea Roma   (Italy)

^d RICHARD STOCKTON COLLEGE OF NEW JERSEY   (United States)

Author keywords

Adherence; Bipolar disorder; Compliance; Unipolar disorder

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE; ZIPRASIDONE;

ANTICHOLINERGIC EFFECT; BEHAVIOR THERAPY; BIPOLAR DISORDER; BODY WEIGHT; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE THERAPY; COHORT ANALYSIS; COMORBIDITY; CONTROLLED DRUG RELEASE; DEMOGRAPHY; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG OVERDOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEALTH BELIEF; HEALTH CARE COST; HEALTH PROGRAM; HOSPITALIZATION; HUMAN; LONG TERM CARE; MAJOR DEPRESSION; MANIA; MOOD DISORDER; MOTIVATION; PATIENT COMPLIANCE; PERSONAL AUTONOMY; PHYSICIAN; PRACTICE GUIDELINE; PREDICTOR VARIABLE; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDY; PSYCHOEDUCATION; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; RECURRENT DISEASE; RELAPSE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIOECONOMICS; SUICIDE; SUICIDE ATTEMPT; SUSTAINED DRUG RELEASE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT REFUSAL; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; DATABASES, BIBLIOGRAPHIC; HUMANS; MEDICATION ADHERENCE; MOOD DISORDERS; PATIENT EDUCATION AS TOPIC; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; SUICIDE; TREATMENT OUTCOME;

EID: 67651061613     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.62     Document Type: Review

References (246)

1. National Institute of Mental Health. The Numbers Count: Mental Disorders in America. NIH MD, USA (2008).
2. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Arch. Gen. Psychiatry 62, 617-627 (2005). (Pubitemid 40973437)
3. US Census Bureau Population Estimates by Demographic Characteristics. Table 2: annual estimates of the population by selected age groups and sex for the United States: April 1, 2000 to July 1, 2004 (NC-EST2004-02). US Census Bureau, Washington, DC, USA (2005).
4. World Health Organization. The World Health Report 2004: Changing History, Annex Table 3: Burden of Disease in DALYs by Cause, Sex, and Mortality Stratum in WHO Regions, Estimates for 2002. WHO, Geneva, Switzerland (2004).
5. Kessler RC, Akiskal HS, Ames M et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am. J. Psychiatry 163, 1561-1568 (2006). (Pubitemid 44465756)
6. Moller HJ, Demyttenaere K, Sacchetti E, Rush AJ, Montgomery SA. Improving the chance of recovery from the short- and long-term consequences of depression. Int. Clin. Psychopharmacol. 18(4), 219-225 (2003). (Pubitemid 36871873)
7. Akerblad AC, Bengtsson F, von Knorring L, Ekselius L. Response, remission and relapse in relation to adherence in primary care treatment of depression: a 2-year outcome study. Int. Clin. Psychopharmacol. 21(2), 117-124 (2006). (Pubitemid 43740320)
8. Demyttenaere K, Enzlin P, Dewe W et al. Compliance with antidepressants in a primary care setting, 2: the influence of gender and type of impairment. J. Clin. Psychiatry 62(Suppl. 22), 34-37 (2001). (Pubitemid 32937584)
9. Peveler R, George C, Kinmonth AL, Campbell M, Thompson C. Effect of antidepressant drug counselling and information leaflets on adherence to drug treatment in primary care: randomised controlled trial. BMJ 319(7210), 612-615 (1999). (Pubitemid 29414560)
10. Melfi CA, Chawla AJ, Croghan TW et al. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch. Gen. Psychiatry 55(12), 1128-1132 (1998).
11. Thase ME, Nierenberg AA, B. Keller MB, Panagides J; Relapse Prevention Study Group. Efficacy of mirtazapine for prevention of depressive relapse: a placebo controlled double-blind trial of recently remitted high-risk patients. J. Clin. Psychiatry 62, 782-788 (2001).
12. Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr. Scand. 105(3), 164-172 (2002).
13. Tacchi MJ, Scott J. Improving Adherence in Schizophrenia and Bipolar Disorders. Wiley, Chichester, UK (2005).
14. Tatarelli R. Drugs and human interactions. Ann. Ist. Super. Sanita 28(2), 197-202 (1992).
15. World Health Organization. Adherence to long-term therapies: evidence for action. WHO, Geneva, Switzerland (2003).
16. Noble LM. Doctor-patient communication and adherence to treatment. In: Adherence to Treatment in Medical Conditions. Myer LB, Midence K (Eds). Wiley, London, UK 51-82 (1998).
17. Depression Guideline Panel. Depression in Primary Care, Volume 2: Treatment of Major Depression, Clinical Practice Guideline, Number 5. US Department of Health and Human Services, Public Health Service, MD, USA (1993).
18. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. Am. J. Psychiatry 157(4 Suppl.), 1-45 (2000).
19. National Collaborating Centre for Mental Health. Depression. Management of Depression in Primary and Secondary Care. National Institute for Clinical Excellence, London, UK (2004).
20. Isometsa E, Lindfors O, Pirkola S et al. The National Finnish current care guidelines for the treatment of depression. An overview. Psychiatr. Fennica 34, 181-196 (2003).
21. Ahrens B, Linden M. Faktoren der Chronifizierung von Depressionen. Munch. Med. Wochenschr. 133, 49-50 (1991).
22. Fritze J. Wie lange sollten Antidepressiva verordnet werden? Psychopharmakotherapie 5, 7-25 (1997).
23. Gilbody S, Whitty P, Grimshaw J, Thomas R. Educational and organizational interventions to improve the management of depression in primary care: a systematic review. JAMA 289, 3145-3151 (2003). (Pubitemid 37432890)
24. Holma IAK, Holma KM, Melartin TK, Isometsa ET. Maintenance pharmacotherapy for recurrent major depressive disorder: 5-year follow-up study. Br. J. Psychiatry 193, 163-164 (2008).
25. Demyttenaere K, Haddad P. Compliance with antidepressant therapy and antidepressant discontinuation symptoms. Acta Psychiatr. Scand. Suppl. 403, 50-56 (2000).
26. Johnson DAW. Treatment of depression in general practice. BMJ 2, 18 (1973).
27. Thompson J, Rankin H, Ashcroft CW et al. The treatment of depression in general practice. Psychol. Med. 12, 741 (1982).
28. Johnson DA. Depression: treatment compliance in general practice. Acta Psychiatr. Scand. Suppl. 290, 447-453 (1981).
29. Hotopf M, Hardy R, Lewis G. Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. Br. J. Psychiatry 170, 120-127 (1997). (Pubitemid 27120644)
30. Robinson P, Bush T, Von Korff M et al. Primary care physician use of cognitive behavioral techniques with depressed patients. J. Fam. Pract. 40(4), 352-357 (1995).
31. Prein RF. Long-term treatment of affective disorders. In: Psychopharmacology. The Third Generation of Progress. Meltzer HY (Ed.). Raven Press, NY, USA 1051-1058 (1987).
32. Maixner SM, Greden JF. Extended antidepressant maintenance and discontinuation syndromes. Depress. Anxiety 8(Suppl. 1), 43-53 (1998).
33. Lin EH, Von Korff M, Katon W et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med. Care 33(1), 67-74 (1995).
34. Bultman DC, Svarstad BL. Effects of pharmacist monitoring on patient satisfaction with antidepressant medication therapy. J. Am. Pharm. Assoc. 42, 36-43 (2002).
35. Frank E, Perel JM, Mallinger AG, Thase ME, Kupfer DJ. Relationship of pharmacologic compliance to long-term prophylaxis in recurrent depression. Psychopharmacol. Bull. 28(3), 231-235 (1992).
36. Sood N, Treglia M, Obenchain RL et al. Determinants of antidepressant treatment outcome. Am. J. Manag. Care 6(12), 1327-1336 (2000).
37. Muller-Oerlinghausen B, Berghofer A, Ahrens B. The antisuicidal and mortality-reducing effect of lithium prophylaxis: consequences for guidelines in clinical psychiatry. Can. J. Psychiatry 48(7), 433-439 (2003). (Pubitemid 37295200)
38. Tondo L, Isacsson G, Baldessarini R. Suicidal behaviour in bipolar disorder: risk and prevention. CNS Drugs 17(7), 491-511 (2003). (Pubitemid 36693704)
39. Craig TJ, Ye Q, Bromet EJ. Mortality among first-admission patients with psychosis. Compr. Psychiatry 47(4), 246-251 (2006).
40. Dutta R, Boydell J, Kennedy N et al. Suicide and other causes of mortality in bipolar disorder: a longitudinal study. Psychol. Med. 37(6), 839-847 (2007). (Pubitemid 46746328)
41. Khalsa HM, Salvatore P, Hennen J et al. Suicidal events and accidents in 216 first-episode bipolar I disorder patients: predictive factors. J. Affect. Disord. 106(1-2), 179-184 (2008).
42. Berk M, Berk L. Mood stabilizers and treatment adherence in bipolar disorder: addressing adverse events. Ann. Clin. Psychiatry 15(3-4), 217-224 (2003). (Pubitemid 38176341)
43. Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch. Gen. Psychiatry 48(12), 1082-1088 (1991).
44. Keck PE Jr, McElroy SL. Outcome in the pharmacologic treatment of bipolar disorder. J. Clin. Psychopharmacol. 16(2 Suppl 1), S15-S23 (1996).
45. Scott J, Pope M. Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization. Am. J. Psychiatry 159(11), 1927-1929 (2002).
46. Coletti DJ, Leigh E, Gallelli KA, Kafantaris V. Patterns of adherence to treatment in adolescents with bipolar disorder. J. Child Adolesc. Psychopharmacol. 15(6), 913-917 (2005). (Pubitemid 43042982)
47. Baldessarini RJ, Tondo L, Faedda GL et al. Latency, discontinuation, and re-use of lithium treatment. In: Lithium in Neuropsychiatry: the Comprehensive Guide. Bauer M, Grof P, Muller-Oerlinghausen B (Eds). Taylor & Francis, London, UK 465-481 (2006).
48. Sajatovic M, Valenstein M, Blow FC, Ganoczy D, Ignacio RV. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord. 8(3), 232-241 (2006).
49. Baldessarini RJ, Perry R, Pike J. Factors associated with treatment nonadherence among US bipolar disorder patients. Hum. Psychopharmacol. 23(2), 95-105 (2008). (Pubitemid 351359581)
50. Post RM, Leverich GS, Altshuler L et al. Lithium-discontinuation induced refractoriness: preliminary observations. Am. J. Psychiatry 149, 1727-1729 (1992).
51. Scott J. Predicting medication non-adherence in severe affective disorders. Acta Neuropsychiatrica 12, 128-130 (2000).
52. Bech P, Vendesborg P, Rafaelsen O. Lithium maintenance treatment of manic-melancholic patients: its role in the daily routine. Acta Psychiatr. Scand. 53, 70-81 (1976).
53. Cochran SD. Compliance with lithium regimens in the out-patient treatment of bipolar affective disorders. J. Compliance Health Care 1, 151-169 (1986).
54. Johnson R, Mcfarland B. Lithium use and discontinuation in a health maintenance organisation. Am. J. Psychiatry 153, 993-1000 (1998). (Pubitemid 26264698)
55. Jamison KR, Gerner RH, Goodwin FK. Patient and physician attitudes toward lithium: relationship to compliance. Arch. Gen. Psychiatry 36(8 Spec. No.), 866-869 (1979).
56. Keck PE Jr, McElroy SL, Strakowski SM, Bourne ML, West SA. Compliance with maintenance treatment in bipolar disorder. Psychopharmacol. Bull. 33(1), 87-91 (1997).
57. Aagaard J, Vestergaard P, Maarbjerg K. Adherence to lithium prophylaxis, 2: multivariate analysis of clinical and psychosocial predictors of non-adherence. Pharmacopsychiatry 21, 166-170 (1988). (Pubitemid 18170301)
58. Danion JM, Neunreuther C, Krieger-Finance F, Imbs JL, Singer L. Compliance with long-term lithium treatment in major affective disorders. Pharmacopsychiatry 20(5), 230-231 (1987). (Pubitemid 18068169)
59. Smith CM, Barzman D, Pristach CA. Effect of patient and family insight on compliance of schizophrenic patients. J. Clin. Pharmacol. 37, 147-154 (1997). (Pubitemid 27131546)
60. Strakowski SM, Keck PE Jr, McElroy SL et al. Twelve-month outcome after a first hospitalization for affective psychosis. Arch. Gen. Psychiatry 55(1), 49-55 (1998).
61. Liraud F, Verdoux H. Caracteristiques cliniques et pronostiques associees a une comorbidite addictive chez des patients hospitalises en psychiatrie. Encephale 26, 16-23 (2000). (Pubitemid 30482340)
62. Verdoux H, Lengronne J, Liraud F et al. Predictors and impact on outcome of medication adherence. A two-year follow-up study of first-admitted subjects with psychosis. Acta Psychiatr. Scand. 102, 203-210 (2000). (Pubitemid 30663329)
63. Manwani SG, Szilagyi KA, Zablotsky B et al. Adherence to pharmacotherapy in bipolar disorder patients with and without co-occurring substance use disorders. J. Clin. Psychiatry 68(8), 1172-1176 (2007). (Pubitemid 47395618)
64. Jamison KR. Medication compliance. In: Manic Depressive Illness. Goodwin FK, Jamison KR (Eds). Oxford University Press, London, UK 756-757 (1990).
65. Fabre L, Abuzzahab F, Amin M et al. Sertraline safety and efficacy in major depression: a double-blind, fixed-dose comparison with placebo. Biol. Psychiatry 38, 592-602 (1995).
66. Preskorn S, Lane R. Sertraline 50 mg daily: the optimal dose in the treatment of depression. Int. J. Psychopharmacol. 10, 129-141 (1995).
67. Thompson C. Management of depression in real-life settings: knowledge gained from large-scale clinical trials. Int. Clin. Psychopharmacol. (Suppl. 3), 21-25 (1994). (Pubitemid 24210925)
68. Revicki DA, Brown RE, Keller MB et al. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. J. Clin. Psychiatry 58(2), 47-58 (1997).
69. Madsen JW, McQuaid JR, Craighead WE. Working with reactant patients: are we prescribing nonadherence? Depress. Anxiety 26, 129-134 (2009).
70. Perahia DG, Quail D, Gandhi P, Walker DJ, Peveler RC. A randomized, controlled trial of duloxetine alone vs. duloxetine plus a telephone intervention in the treatment of depression. J. Affect. Disord. 108(1-2), 33-41 (2008).
71. Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin. Ther. 25(8), 2289-2304 (2003).
72. Toni C, Pertugi G, Frare F, Mata B, Akiskal HS. Spontaneous treatment discontinuation in panic disorder patients treated with antidepressants. Acta Psychiatr. Scand. 110, 130-137 (2004). (Pubitemid 38969525)
73. Curtis GC, Massana J, Udina C, Ayuso JL, Perugi G. Maintenance of drug therapy of panic disorder. J. Psychiatr. Res. 27(Suppl. 1), 127-142 (1993). (Pubitemid 24036528)
74. Toni C, Perugi G, Frare F et al. A prospective naturalistic study of 326 panic-agoraphobic patients treated with antidepressants. Pharmacopsychiatry 33, 1-11 (2000).
75. Bollini P, Tibaldi G, Testa C, Munizza C. Understanding treatment adherence in affective disorders: a qualitative study. J. Psychiatr. Ment. Health Nurs. 11, 668-674 (2004). (Pubitemid 39592656)
76. Fava M. Prospective studies of adverse events related to antidepressant discontinuation. J. Clin. Psychiatry 67(Suppl. 4), 14-21 (2006). (Pubitemid 43764533)
77. Nemeroff CB. New directions in the development of antidepressants: the interface of neurobiology and psychiatry. Hum. Psychopharmacol. 17(Suppl. 1), S13-S16 (2002).
78. Grimshaw JM, Thomas RE, MacLennan G et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol. Assess. 8, 1-72 (2004). (Pubitemid 38279464)
79. Verkerk K, Van Veenendaal H, Severens JL, Hendriks EJ, Burgers JS. Considered judgment in evidence-based guideline development. Int. J. Qual. Health Care 18, 365-369 (2006). (Pubitemid 44468821)
80. Katon W, von Korff M, Lin E, Bush T, Ormel J. Adequacy and duration of antidepressant treatment in primary care. Med. Care 30(1), 67-76 (1992).
81. Delgado PL. Approaches to the enhancement of patient adherence to antidepressant medication treatment. J. Clin. Psychiatry 61(Suppl. 2), 6-9 (2000).
82. Aikens JE, Kroenke K, Swindle RW, Eckert GJ. Nine-month predictors and outcomes of SSRI antidepressant continuation in primary care. Gen. Hosp. Psychiatry 27, 229-236 (2005). (Pubitemid 40898247)
83. Schwenk TL, Evans DL, Laden SK, Lewis L. Treatment outcome and physician-patient communication in primary care patients with chronic, recurrent depression. Am. J. Psychiatry 161(10), 1892-1901 (2004).
84. Givens JL, Datto CJ, Ruckdeschel K et al. Older patients' aversion to antidepressants: a qualitative study. J. Gen. Intern. Med. 21, 146-151 (2006). (Pubitemid 43363670)
85. Leventhal H, Diefenbach M, Leventhal EA. Illness cognition: using common sense to understand treatment adherence and affect cognition treatment. Cognit. Ther. Res. 16, 143-163 (1992).
86. Brown C, Dunbar-Jacob J, Palenchar DR et al. Primary care patients' personal illness models for depression: a preliminary investigation. Fam. Pract. 18, 314-320 (2001). (Pubitemid 32514688)
87. Sullivan MD, Katon WJ, Russo JE et al. Patient beliefs predict response to paroxetine among primary care patients with dysthymia and minor depression. J. Am. Board Fam. Pract. 16, 22-31 (2003).
88. Aikens JE, Nease DE Jr, Klinkman MS. Explaining patients' beliefs about the necessity and harmfulness of antidepressants. Ann. Fam. Med. 6(1), 23-29 (2008).
89. Fawcett J. Compliance: definitions and key issues. J. Clin. Psychiatry 56(Suppl. 1), 4-8 (1995).
90. Paykel ES. Psychotherapy, medication combinations, and compliance. J. Clin. Psychiatry 56(Suppl. 1), 24-30 (1995).
91. Bultman D, Svarstad B. Effects of physician communication style on client medication beliefs and adherence with antidepressant treatment. Patient Educ. Couns. 40, 173-185 (2000). (Pubitemid 30195758)
92. Frank E, Kupfer DJ, Siegel LR. Alliance not compliance: a philosophy of outpatient care. J. Clin. Psychiatry 56(Suppl. 1), 11-16 (1995).
93. Woller KM, Buboltz WC Jr, Loveland JM. Psychological reactance: examination across age, ethnicity, and gender. Am. J. Psychol. 120(1), 15-24 (2007).
94. Brehm JW. A Theory of Psychological Reactance. Academic Press, NY, USA (1966).
95. Brehm JW, Brehm SS. Psychological Reactance. Wiley, NY, USA (1981).
96. Fogarty JS. Reactance theory and patient nonadherence. Soc. Sci. Med. 45, 1277-1288 (1997).
97. Seibel CA, Dowd ET. Reactance and therapeutic noncompliance. Cognit. Ther. Res. 23, 373-379 (1999).
98. Beutler LE, Engle D, Mohr D et al. Predictors of differential response to cognitive, experiential, and self-directed psychotherapeutic procedures. J. Consult. Clin. Psychol. 59(2), 333-340 (1991).
99. Karno MP, Longabaugh R. Less directiveness by therapists improves drinking outcomes of reactant clients in alcoholism treatment. J. Consult. Clin. Psychol. 73(2), 262-267 (2005). (Pubitemid 40446381)
100. Karno MP, Longabaugh R. An examination of how therapist directiveness interacts with patient anger and reactance to predict alcohol use. J. Stud. Alcohol 66(6), 825-832 (2005). (Pubitemid 41688805)
101. American Psychiatric Association. Practice Guidelines for the Treatment of Patients with Bipolar Disorder. American Psychiatric Association, Washington, DC, USA (2002).
102. Guscott R, Taylor L. Lithium prophylaxis in recurrent affective illness: efficacy, effectiveness and efficiency. Br. J. Psychiatry 164, 741-746 (1994). (Pubitemid 24186893)
103. Jamison KR, Akiskal HS. Medication compliance in patients with bipolar disorder. Psychiatr. Clin. North Am. 6(1), 175-192 (1983).
104. Maarbjerg K, Aagaard J, Vestergaard P. Adherence to lithium prophylaxis: I. Clinical predictors and patient's reasons for nonadherence. Pharmacopsychiatry 21(3), 121-125 (1988). (Pubitemid 18147251)
105. Gitlin MJ, Cochran SD, Jamison KR. Maintenance lithium treatment: side effects and compliance. J. Clin. Psychiatry 50(4), 127-131 (1989).
106. Keck PE Jr, McElroy SL, Strakowski SM et al. Factors associated with pharmacologic noncompliance in patients with mania. J. Clin. Psychiatry 57(7), 292-297 (1996).
107. Weiss RD, Greenfield SF, Najavits LM et al. Medication compliance among patients with bipolar disorder and substance use disorder. J. Clin. Psychiatry 59(4), 172-174 (1998).
108. Baldessarini RJ. Enhancing treatment with psychotropic medicines. Bull. Menninger Clin. 58(2), 224-241 (1994).
109. DelBello MP, Hanseman D, Adler CM, Fleck DE, Strakowski SM. Twelvemonth outcome of adolescents with bipolar disorder following first hospitalization for a manic or mixed episode. Am. J. Psychiatry 164(4), 582-590 (2007). (Pubitemid 46650189)
110. Scott J, Pope M. Nonadherence with mood stabilizers: prevalence and predictors. J. Clin. Psychiatry 63(5), 384-390 (2002). (Pubitemid 34507214)
111. Miklowitz DJ. Longitudinal outcome and medication non-compliance among manic patients with and without mood-incongruent psychotic features. J. Nerv. Ment. Dis. 180, 703-711 (1992).
112. Yerevanian BI, Koek RJ, Mintz J. Bipolar pharmacotherapy and suicidal behavior. Part I: lithium, divalproex and carbamazepine. J. Affect. Disord. 103(1-3), 5-11 (2007). (Pubitemid 47445781)
113. Greenhouse WJ, Meyer B, Johnson SL. Coping and medication adherence in bipolar disorder. J. Affect. Disord. 59(3), 237-241 (2000). (Pubitemid 30347547)
114. Trauer T, Sacks T. The relationship between insight and medication adherence in severely mentally ill clients treated in the community. Acta Psychiatr. Scand. 102, 211-216 (2000). (Pubitemid 30663330)
115. Kleindienst N, Greil W. Are illness concepts a powerful predictor of adherence to prophylactic treatment in bipolar disorder? J. Clin. Psychiatry 65(7), 966-974 (2004).
116. Yen CF, Chen CS, Ko CH et al. Relationships between insight and medication adherence in outpatients with schizophrenia and bipolar disorder: prospective study. Psychiatry Clin. Neurosci. 59, 403-409 (2005).
117. Schumann C, Lenz G, Berghofer A, Muller-Oerlinghausen B. Non-adherence with long-term prophylaxis: a 6-year naturalistic follow-up study of affectively ill patients. Psychiatry Res. 89(3), 247-257 (1999). (Pubitemid 30053007)
118. Connelly CE, Davenport YB, Nurnberger JI Jr. Adherence to treatment regimen in a lithium carbonate clinic. Arch. Gen. Psychiatry 39(5), 585-588 (1982).
119. Keck PE Jr, McElroy SL, Strakowski SM et al. 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am. J. Psychiatry 155(5), 646-652 (1998).
120. Cochran SD. Preventing medical noncompliance in the outpatient treatment of bipolar affective disorders. J. Consult. Clin. Psychol. 52(5), 873-878 (1984).
121. Fletcher RH. Patient compliance with therapeutic advice: a modern view. Mount Sinai J. Med. 56, 453-458 (1989).
122. Edelman R, Eitel P, Wadhwa NK et al. Accuracy or bias in nurses ratings of patient compliance: a comparison of treatment modality. Peritoneal Dialysis Int. 16, 321-325 (1996). (Pubitemid 26202712)
123. Norell SE. Accuracy of patients interviews and estimates by clinical staff determining medication compliance. Social Sci. Med. 15, 57-61 (1981).
124. Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. J. Clin. Psychiatry 69(Suppl. 1), 4-17 (2008).
125. Gianfrancesco FD, Sajatovic M, Tafesse E, Wang RH. Association between antipsychotic combination therapy and treatment adherence among individuals with bipolar disorder. Ann. Clin. Psychiatry 21(1), 3-16 (2009).
126. Gianfrancesco FD, Sajatovic M, Rajagopalan K, Wang RH. The association between treatment adherence and antipsychotic dose among individuals with bipolar disorder. Int. Clin. Psychopharmacol. 23(6), 305-316 (2008).
127. Gianfrancesco FD, Sajatovic M, Rajagopalan K, Wang RH. Antipsychotic treatment adherence and associated mental health care use among individuals with bipolar disorder. Clin. Ther. 30(7), 1358-1374 (2008).
128. Miasso AI, Cassiani SH, Pedrao LJ. Bipolar affective disorder and medication therapy: identifying barriers. Rev. Lat. Am. Enfermagem 16(4), 739-745 (2008).
129. Hassan M, Lage MJ. Risk of rehospitalization among bipolar disorder patients who are nonadherent to antipsychotic therapy after hospital discharge. Am. J. Health Syst. Pharm. 66(4), 358-365 (2009).
130. Sajatovic M, Biswas K, Kilbourne AK et al. Factors associated with prospective long-term treatment adherence among individuals with bipolar disorder. Psychiatr. Serv. 59(7), 753-759 (2008).
131. Sajatovic M, Blow FC, Kales HC et al. Age comparison of treatment adherence with antipsychotic medications among individuals with bipolar disorder. Int. J. Geriatr. Psychiatry 22(10), 992-998 (2007). (Pubitemid 47616773)
132. Hassan M, Madhavan SS, Kalsekar ID et al. Comparing adherence to and persistence with antipsychotic therapy among patients with bipolar disorder. Ann. Pharmacother. 41(11), 1812-1818 (2007).
133. Gianfrancesco FD, Rajagopalan K, Sajatovic M, Wang RH. Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychotics. J. Clin. Psychiatry 67(2), 222-232 (2006). (Pubitemid 43357468)
134. Angst J, Sellaro R, Angst F. Long-term outcome and mortality of treated vs. untreated bipolar and depressed patients: a preliminary report. Int J. Psychiatr. Clin. Pract. 2, 115-119 (1998). (Pubitemid 28313960)
135. Clark DC, Goebel-Fabbri AE. Lifetime risk of suicide in major affective disorders. In: Harvard Medical School Guide to Assessment and Intervention in Suicide. Jacobs D (Ed.). Jossey Bass, CA, USA 270-286 (1998).
136. Baldessarini RJ, Jamison KR. Effects of medical interventions on suicidal behavior: summary and conclusions. J. Clin. Psychiatry 60(Suppl. 2), 117-122 (1999).
137. Brodersen A, Licht RW, Vestergaard P, Olesen AV, Mortensen PB. Sixteen year mortality in patients with affective disorder commenced on lithium. Br. J. Psychiatry 176, 419-433 (2000).
138. Tondo L, Baldessarini RJ. Reduced suicide risk during lithium maintenance treatment. J. Clin. Psychiatry 61(Suppl. 9), 97-104 (2000). (Pubitemid 30453892)
139. Guze SB, Robins E. Suicide and primary affective disorders. Br. J. Psychiatry 117, 437-438 (1970).
140. Roy A. Suicide. In: Comprehensive Textbook of Psychiatry. Kaplan HI, Sadock BJ (Eds). Williams & Wilkins, MD, USA 1414-1427 (1989).
141. Angst J, Stassen HH, Gross G, Huber G, Stone MH. Suicide in affective and schizoaffective disorders. In: Affective and Schizoaffective Disorders. Marneros A, Tsuang MT (Eds). Springer-Verlag, Berlin, Germany 168-185 (1990).
142. Angst J, Angst F, Stassen HS. Suicide risk in patients with major depressive disorder. J. Clin. Psychiatry 60(Suppl. 2), 57-62 (1999). (Pubitemid 29101964)
143. Diekstra RFW. The epidemiology of suicide and parasuicide. Acta Psychiatr. Scand. 87(Suppl. 371), 9-20 (1993).
144. Inskip HM, Harris EC, Barraclough BB. Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia. Br. J. Psychiatry 172, 35-37 (1998).
145. Keller MB, Lavori PW, Klerman GL et al. Low levels and lack of predictors of somatotherapy and psychotherapy received by depressed patients. Arch. Gen. Psychiatry 3, 458-466 (1986).
146. Mccombs JS, Nichol MB, Stimmel GL et al. Cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population. J. Clin. Psychiatry 51(Suppl. 6), 60-69 (1990).
147. Isacsson G, Boëthius G, Bergman U. Low level of antidepressant prescription for people who later commit suicide: 15 years of experience from a population-based drug database in Sweden. Acta Psychiatr. Scand. 85, 444-448 (1992).
148. Baldessarini RJ, Tondo L, Suppes T, Faedda GL, Tohen M. Pharmacological treatment of bipolar disorder throughout the life-cycle. In: Bipolar Disorder Through the Life-Cycle. Shulman KI, Tohen M, Kutcher S (Eds). John Wiley & Sons, NY, USA 299-338 (1996).
149. Suominen KH, Isometsa E, Hendriksson MM, Ostamo AI, Lonnqvist JK. Inadequate treatment for major depression both before and after attempted suicide. Am. J. Psychiatry 155, 1778-1780 (1998). (Pubitemid 28547508)
150. Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J. Clin. Psychiatry 60(Suppl. 2), 77-84 (1999). (Pubitemid 29101967)
151. Teicher MH, Glod CA, Cole JO. Antidepressant drugs and the emergence of suicidal tendencies. Drug Saf. 3, 186-212 (1993).
152. Perry PJ. Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic vs. selective serotonin reuptake inhibitor antidepressants. J. Affect. Disord. 39, 1-6 (1996).
153. Muller-Oerlinghausen B, Berghöfer A. Antidepressants and suicidal risk. J. Clin. Psychiatry 60(Suppl. 2), 94-99 (1999).
154. Baldessarini RJ, Ioanitescu D, Ragade J et al. Suicide risk and antidepressant treatment: a meta-analysis. Acta Psychiatr. Scand. 104, 163-172 (2001).
155. Freemantle N, House A, Song F, Mason JM, Sheldon TA. Prescribing selective serotonin reuptake inhibitors as strategy for prevention of suicide. BMJ 309, 249-253 (1994). (Pubitemid 24252664)
156. Ohberg A, Lonqvist J, Sarna S, Vuori E, Penttila A. Trends and availability of suicide methods in Finland: proposals for restrictive measures. Br. J. Psychiatry 166, 35-43 (1995).
157. Zornberg GL, Pope HG Jr. Treatment of depression in bipolar disorder: new directions for research. J. Clin. Psychopharmacol. 13, 397-408 (1993).
158. Tondo L, Baldessarini RJ, Hennen J, Floris G. Lithium maintenance treatment of depression and mania in bipolar I and bipolar II disorders. Am. J. Psychiatry 155(5), 638-645 (1998). (Pubitemid 28225404)
159. Baldessarini RJ, Tondo L, Davis P et al. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord. 8(5 Pt 2), 625-639 (2006). (Pubitemid 44567144)
160. Guzzetta F, Tondo L, Centorrino F, Baldessarini RJ. Lithium treatment reduces suicide risk in recurrent major depressive disorder. J. Clin. Psychiatry 68(3), 380-383 (2007). (Pubitemid 46506801)
161. Tondo L, Baldessarini RJ, Hennen J et al. Lithium treatment and risk of suicidal behavior in bipolar disorder patients. J. Clin. Psychiatry 59(8), 405-414 (1998). (Pubitemid 28391562)
162. Johnson RE, McFarland BH. Lithium use and discontinuation in a health maintenance organization. Am. J. Psychiatry 153(8), 993-1000 (1996).
163. Strober M, Morrell W, Lampert C, Burroughs J. Relapse following discontinuation of lithium maintenance therapy in adolescents with bipolar I illness: a naturalistic study. Am. J. Psychiatry 147(4), 457-461 (1990). (Pubitemid 20107110)
164. Suppes T, Baldessarini RJ, Faedda GL, Tondo L, Tohen M. Discontinuation of maintenance treatment in bipolar disorder: risks and implications. Harv. Rev. Psychiatry 1(3), 131-144 (1993).
165. Tondo L, Baldessarini RJ. Reduced suicide risk during lithium maintenance treatment. J. Clin. Psychiatry 61(Suppl. 9), 97-104 (2000). (Pubitemid 30453892)
166. Gonzales-Pinto A, Mosuera F, Alonso M et al. Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. Bipolar Disord. 8, 618-621 (2006). (Pubitemid 44567143)
167. Dalton EJ, Cate-Carter TD, Mundo E et al. Suicide risk in bipolar patients: the role of co-morbid substance use disorders. Bipolar Disord. 5, 58-61 (2003). (Pubitemid 36621635)
168. Feinman JA, Dunner DL. The effect of alcohol and substance abuse on the course of bipolar affective disorder. J. Affect. Disord. 37, 43-49 (1996).
169. Goldberg JF. Optimizing treatment outcomes in bipolar disorder under ordinary conditions. J. Clin. Psychiatry 69(Suppl. 3), 11-19 (2008).
170. Tondo L, Hennen J, Baldessarini RJ. Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr. Scand. 104(3), 163-172 (2001). (Pubitemid 32762270)
171. Yerevanian BI, Koek RJ, Mintz J. Bipolar pharmacotherapy and suicidal behavior part 3: impact of antipsychotics. J. Affect. Disord. 103(1-3), 23-28 (2007). (Pubitemid 47445780)
172. Yerevanian BI, Koek RJ, Mintz J, Akiskal HS. Bipolar pharmacotherapy and suicidal behavior part 2. The impact of antidepressants. J. Affect. Disord. 103(1-3), 13-21 (2007). (Pubitemid 47445779)
173. Pampallona S, Bollini P, Tibaldi G et al. Combined pharmacotherapy and psychological treatment for depression: a systematic review. Arch. Gen. Psychiatry 61, 714-719 (2004). (Pubitemid 38890806)
174. Sajatovic M, Davies M, Hrouda DR. Enhancement of treatment adherence among patients with bipolar disorder. Psychiatr. Serv. 55(3), 264-269 (2004). (Pubitemid 38298810)
175. Clarkin JF, Carpenter D, Hull J, Wilner P, Glick I. Effects of psychoeducational intervention for married patients with bipolar disorder and their spouses. Psychiatr. Serv. 49, 531-533 (1998). (Pubitemid 28175695)
176. Anderson C, Griffin S, Rossi A et al. A comparative study of the impact of education vs process groups for families of patients with affective disorders. Fam. Process 25, 185-205 (1986).
177. van Gent EM, Zwart FM. Psychoeducation of partners of bipolar-manic patients. J. Affect. Disord. 21(1), 15-18 (1991).
178. Bauer MS, Wisniewski SR, Marangell LB et al. Are antidepressants associated with new-onset suicidality in bipolar disorder? A prospective study of participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). J. Clin. Psychiatry 67, 48-55 (2006).
179. Miklowitz DJ, George EL, Richards JA et al. A randomised study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Arch. Gen. Psychiatry 60, 904-912 (2003).
180. Berk M, Berk L, Castle D. A collaborative approach to the treatment alliance in bipolar disorder. Bipolar Disord. 6, 504-518 (2004). (Pubitemid 39562418)
181. Cohen NL, Ross EC, Bagby RM, Farvolden P, Kennedy SH. The 5-factor model of personality and antidepressant medication compliance. Can. J. Psychiatry 49(2), 106-113 (2004). (Pubitemid 38387419)
182. Higgins N, Livingston G, Katona C. Concordance therapy: an intervention to help older people take antidepressants. J. Affect. Disord. 81(3), 287-291 (2004). (Pubitemid 39141919)
183. Kemp R, Hayward P, Applewhaite G et al. Compliance therapy in psychotic patients: randomised controlled trial. BMJ 312, 345-349 (1996). (Pubitemid 26050038)
184. Scott J, Tacchi MJ. A pilot study of concordance therapy for individuals with bipolar disorders who are non-adherent with lithium prophylaxis. Bipolar Disord. 4, 386-392 (2002). (Pubitemid 36041468)
185. Altamura AC, Mauri M. Plasma concentrations, information and therapy adherence during long-term treatment with antidepressants. Br. J. Clin. Pharmacol. 20(6), 714-716 (1985). (Pubitemid 16184119)
186. Robinson P, Katon W, Von Korff M et al. The education of depressed primary care patients: what do patients think of interactive booklets and a video? J. Fam. Pract. 44(6), 562-571 (1997). (Pubitemid 27255348)
187. Haynes R, Mckibbon K, Kanani R. Systematic review of randomized trials of interventions to assist patients to follow prescriptions for medications. Lancet 348, 383-396 (1996). (Pubitemid 26261515)
188. Kutcher S, Leblanc J, Maclaren C, Hadrava V. A randomized trial of a specific adherence enhancement program in sertraline-treated adults with major depressive disorder in a primary care setting. Prog. Neuropsychopharmacol. Biol. Psychiatry 26, 591-596 (2002). (Pubitemid 34252956)
189. Hoffman L, Enders J, Luo J et al. Impact of an antidepressant management program on medication adherence. Am. J. Manag. Care 9(1), 70-80 (2003). (Pubitemid 36187577)
190. Donohue JM, Berndt ER, Rosenthal M, Epstein AM, Frank RG. Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression. Med. Care 42(12), 1176-1185 (2004). (Pubitemid 39627294)
191. Depp CA, Moore DJ, Patterson TL, Lebowitz BD, Jeste DV. Psychosocial interventions and medication adherence in bipolar disorder. Dialogues Clin. Neurosci. 10(2), 239-250 (2008).
192. Vieta E. Improving treatment adherence in bipolar disorder through psychoeducation. J. Clin. Psychiatry 66(Suppl. 1), 24-29 (2005). (Pubitemid 350042454)
193. Gonzalez-Pinto A, Gonzalez C, Enjuto S et al. Psychoeducation and cognitive - behavioral therapy in bipolar disorder: an update. Acta Psychiatr. Scand. 109, 83-90 (2004). (Pubitemid 38186818)
194. Colom F, Vieta E, Martinez-Aran A et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch. Gen. Psychiatry 60(4), 402-407 (2003). (Pubitemid 36403001)
195. Vergouwen AC, Bakker A, Katon WJ, Verheij TJ, Koerselman F. Improving adherence to antidepressants: a systematic review of interventions. J. Clin. Psychiatry 64(12), 1415-1420 (2003). (Pubitemid 41270098)
196. Roter D, Hall J, Merisca R et al. Effectiveness of interventions to improve patient compliance: a meta-analysis. Med. Care 36, 1138-1161 (1998). (Pubitemid 128456406)
197. Haynes RB, McDonald H, Garg AX, Montague P. Interventions for helping patients to follow prescriptions for medication. Cochrane Database Syst. Rev. 2, CD000011 (2002).
198. Colom F, Lam D. Psychoeducation: improving outcomes in bipolar disorder. Eur. Psychiatry 20, 359-364 (2005). (Pubitemid 41318000)
199. Reinares M, Colom F, Martinez-Aran A, Benabarre A, Vieta E. Therapeutic interventions focused on the family of bipolar patients. Psychother. Psychosom. 71(1), 2-10 (2002).
200. Scott J, Wright J. Cognitive therapy for severe mental disorders. In: Review of Psychiatry. APA Press, Washington, DC, USA 135-170 (1997).
201. Goodwin FK, Jamison KR. Manic-Depressive Illness. Oxford University Press, NY, USA (2007).
202. Frank E, Kupfer DJ, Perel JM et al. Three year outcomes in maintenance therapies in recurrent depression. Arch. Gen. Psychiatry 47, 1093-1099 (1990).
203. Myers ED, Calvert EJ. Information, compliance and side effects: a study of patients on antidepressant medication. Br. J. Clin. Pharmacol. 17, 21-25 (1984).
204. Seltzer A, Roncari I, Garfinkel P. Effect of patient education on medication compliance. Can. J. Psychiatry 25(8), 638-645 (1980). (Pubitemid 11195893)
205. Essex B, Roig R, Renshaw J. Pilot study of records of shared care for people with mental illnesses. BMJ 300, 1442-1446 (1990). (Pubitemid 20195328)
206. Bodenheimer T, Wagner E, Grumbach K. Improving primary care for patients with chronic illness - the chronic care model. Part 2. JAMA 288, 1909-1914 (2002).
207. Coulter A, Elwyn G. What do patients want from high quality general practice and how do we involve them in improvement? Br. J. Gen. Pract. 52, S22-S26 (2002).
208. van Os T, Ormel J, van den Brink R et al. Training primary care physicians improve the management of depression. Gen. Hosp. Psychiatry 21, 168-176 (1999). (Pubitemid 29278011)
209. Von Korff M, Goldberg D. Improving outcomes in depression - the whole process of care needs to be enhanced. BMJ 323, 948-949 (2001).
210. Fuertes JN, Boylan LS, Fontanella JA. Behavioral indices in medical care outcome: the working alliance, adherence, and related factors. J. Gen. Intern. Med. 24, 80-85 (2008).
211. Lam DH, Watkins ER, Hayward P et al. A randomized controlled study of cognitive therapy of relapse prevention for bipolar affective disorder: outcome of the first year. Arch. Gen. Psychiatry 60, 145-152 (2003). (Pubitemid 36173120)
212. Lam DH, Bright J, Jones S et al. Cognitive therapy for bipolar illness: a pilot study of relapse prevention. Cognit. Ther. Res. 24, 503-520 (2000). (Pubitemid 30663145)
213. Schmitz JM, Oswald LM, Jacks SD et al. Relapse prevention treatment for cocaine dependence: group vs. individual format. Addict. Behav. 22(3), 405-418 (1997).
214. Scott J, Paykel E, Morriss R et al. Cognitive-behavioural therapy for severe and recurrent bipolar disorders: randomised controlled trial. Br. J. Psychiatry 188, 313-320 (2006).
215. Ball JR, Mitchell PB, Corry JC et al. A randomized controlled trial of cognitive therapy for bipolar disorder: focus on long-term change. J. Clin. Psychiatry 67(2), 277-286 (2006).
216. Papageorgiou A, King M, Janmohamed A, Davidson O, Dawson J. Advance directives for patients compulsorily admitted to hospital with serious mental illness. Randomised controlled trial. Br. J. Psychiatry 181, 513-519 (2002). (Pubitemid 35440677)
217. Johnson M, Griffiths R, Piper M, Langdon R. Risk factors for an untoward medication event among elders in community-based nursing caseloads in Australia. Public Health Nurs. 22(1), 36-44 (2005). (Pubitemid 40238772)
218. Simoneau TL, Miklowitz DJ, Richards JA, Saleem R, George EL. Bipolar disorder and family communication: effects of a psychoeducational treatment program. J. Abnorm. Psychol. 108, 588-597 (1999).
219. Scott J. Psychotherapy for bipolar disorder. Br. J. Psychiatry 167, 581-588 (1995).
220. Myers ED, Branthwaite A. Out-patient compliance with antidepressant medication. Br. J. Psychiatry 160, 83-86 (1992).
221. Van Putten T. Why do patients with manic-depressive illness stop their lithium? Compr. Psychiatry 16, 179-183 (1975).
222. Blackwell B. Treatment adherence. Br. J. Psychiatry 129, 513-531 (1976).
223. Salzman C. Medication compliance in the elderly. J. Clin. Psychiatry 56(Suppl. 1), 18-22 (1995).
224. Adams J, Scott J. Predicting medication adherence in severe mental disorders. Acta Psychiatr. Scand. 101, 119-124 (2000). (Pubitemid 30084422)
225. Howard K, Rickels K, Mock JE et al. Therapeutic style and attrition rates from psychiatric drug treatment. J. Nerv. Ment. Dis. 150, 102-110 (1970).
226. Milburn HJ, Cochran GM. Letter: treating the patient as a decision maker is not always appropriate. BMJ 314, 1906 (1997).
227. Mullen PD. Compliance becomes concordance. BMJ 314, 691-692 (1997).
228. Kampman O, Lehtinen K. Compliance in psychoses. Acta Psychiatr. Scand. 100, 167-175 (2000).
229. Fenton WS, Blyler CB, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr. Bull. 23, 637-651 (1997).
230. Luoma JB, Martin CE, Pearson JL. Contact with mental health and primary care providers before suicide: a review of the evidence. Am. J. Psychiatry 159, 909-916 (2002).
231. Rihmer Z, Barsi J, Veg K, Katona CL. Suicide rates in Hungary correlate negatively with reported rates of depression. J. Affect. Disord. 20, 87-91 (1990). (Pubitemid 20316950)
232. Rihmer Z, Rutz W, Barsi J. Suicide rate, prevalence of diagnosed depression and prevalence of working physicians in Hungary. Acta Psychiatr. Scand. 88, 391-394 (1993). (Pubitemid 24001700)
233. Baldessarini RJ, Tondo L. Recurrence risk in bipolar manic-depressive disorders after discontinuing lithium maintenance treatment: an overview. Clin. Drug Investig. 15(4), 337-351 (1998). (Pubitemid 28204008)
234. Aagaard J, Vestergaard P. Predictors of outcome in prophylactic lithium treatment: a 2-year prospective study. J. Affect. Disord. 18(4), 259-266 (1990). (Pubitemid 20127123)
235. Regier DA, Narrow WE, Rae DS et al. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch. Gen. Psychiatry 50(2), 85-94 (1993).
236. Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br. J. Psychiatry 170, 205-228 (1997). (Pubitemid 27117683)
237. Colom F, Vieta E, Martinez-Aran A et al. Clinical factors associated with treatment noncompliance in euthymic bipolar patients. J. Clin. Psychiatry 61(8), 549-555 (2000). (Pubitemid 30677968)
238. Pompili M, Rihmer Z, Innamorati M et al. Assessment and treatment of suicide risk in bipolar disorders. Expert Rev. Neurother. 9(1), 109-136 (2009).
239. Stephenson BJ, Rowe BH, Haynes RB, Macharia WM, Leon G. Is this patient taking the treatment as prescribed? JAMA 269, 2779-2781 (1993).
240. Harvey N, Summerton A, Forrest A, Peet M. Compliance, the LAQ and a new laboratory method of measuring RBC lithium. J. Clin. Psychiatry 51, 126-127 (1990). (Pubitemid 20107914)
241. Gengo F, Frazer A, Ramsey TA, Mendels J. The lithium ratio as a guide to patient compliance. Compr. Psychiatry 21(4), 276-280 (1980). (Pubitemid 10027834)
242. Harvey NS, Peet M. Lithium maintenance: 2. Effects of personality and attitude on health information acquisition and compliance. Br. J. Psychiatry 158, 200-204 (1991).
243. Kelly GR, Mamon JA, Scott JE. Utility of the health belief model in examining medication compliance among psychiatric outpatients. Soc. Sci. Med. 25(11), 1205-1211 (1987).
244. van Geffen EC, Gardarsdottir H, van Hulten R et al. Initiation of antidepressant therapy: do patients follow the GP's prescription? Br. J. Gen. Pract. 59(559), 81-87 (2009).
245. ten Doesschate MC, Bockting CL, Koeter MW, Schene AH. Predictors of nonadherence to continuation and maintenance antidepressant medication in patients with remitted recurrent depression. J. Clin. Psychiatry 70(1), 63-69 (2009).
246. Yen CF, Lee Y, Tang TC et al. Predictive value of self-stigma, insight, and perceived adverse effects of medication for the clinical outcomes in patients with depressive disorders. J. Nerv. Ment. Dis. 197(3), 172-177 (2009).